Table 1. Patient characteristics (n=127).
| Variables | n (%) | Median (range) |
|---|---|---|
| Age (years) | 60 (27–83) | |
| Sex, M: F | 70 (55): 57 (45) | |
| Type of myeloma | ||
| IgG | 67 (52) | |
| IgA | 31 (24) | |
| IgM | 2 (2) | |
| IgD | 2 (2) | |
| Biclonal (G, A) | 2 (2) | |
| Light-chain MM | 22 (17) | |
| Non-secretory | 1 (1) | |
| Kappa/lambda | 81 (64)/45 (36) | |
| Intramedullary/extramedullary | 118 (93)/9 (7) | |
| AL/AH amyloidosis | 2 (2) | |
| Salmon and Durie stage | ||
| I | 11 (9) | |
| II/III | 116 (91) | |
| A/B | 108 (85)/19 (15) | |
| ISS stage (n=75) | ||
| I | 44 (59) | |
| II | 11 (15) | |
| III | 20 (26) | |
| KPS (%) | 90 (40–100) | |
| BMI (kg/m2) | 24 (15–36) | |
| Beta-2 microglobulin (mg/dl) | 79 (62) | 3 (1.1–23) |
| PC BM infiltration rate (%) | 72 (57) | 31 (0–90) |
| Creatinine (mg/dl) | 0.8 (0.4–7.4) | |
| eGFR (MDRD, ml/min/1.73m2) | 88 (6–182) | |
| CKD stages | ||
| 1: eGFR ⩾90 ml/min/1.73m2 | 62 (49) | |
| 2: eGFR 89–60 ml/min/1.73m2 | 31 (24) | |
| 3: eGFR 59–30 ml/min/1.73m2 | 22 (17) | |
| 4: eGFR 29–15 ml/min/1.73m2 | 6 (5) | |
| 5: eGFR <15 ml/min/1.73m2 | 6 (5) | |
| Cytogenetics (FISH) | 56 (44) | |
| Deletion 13q14 | 16 (29) | |
| Standard therapy : auto PBSCT | 65 (51): 62 (49) | |
Abbreviations: AH, amyloid heavy; AL, amyloid light; auto-PBSCT, autologous peripheral blood stem cell transplantation; BMI, body mass index; CKD, chronic kidney disease stages according to the K/DOQI guidelines defined by MDRD; eGFR, estimated glomerular filtration rate; F, female; FISH, fluorescent in situ hybridization; Ig, immunoglobulin; ISS, International Staging System; KPS, Karnofsky Performance Status; M, male; MDRD, Modification of Diet in Renal Disease; MM, multiple myeloma; PC BM infiltration rate, plasma cell bone marrow infiltration rate; estimated GFR (ml/min/1.73m2)=186 × (serum creatinine level (in milligrams per decilitre))−1.154 × (age (in years))−0.203 × (0.742, if female, 1.21, if black).